Pig Kidney Bridge: Record Nine-Month Survival Paves Way for Human Transplant

Key points

• Tim Andrews, a 66-year-old patient with type 2 diabetes-induced kidney failure, received a kidney from a Yucatan miniature pig named Wilma on January 25, 2025.
• The pig kidney underwent 69 genetic edits, including the removal of three proteins that trigger immune rejection and the addition of seven human genes to improve compatibility.
• Andrews remained off dialysis for 271 days, the longest recorded survival for a pig kidney xenograft, before the organ failed due to vascular damage.
• After returning to dialysis for approximately three months, Andrews received a human kidney from a deceased donor in January 2026, which functioned well during follow-up.
• No new antibodies against human tissue were detected, confirming the pig kidney did not hinder the success of the subsequent human transplant.
• eGenesis, the biotech company behind the technology, has received FDA approval for an expanded trial involving 33 patients across 10 US centers, aiming for marketing approval by 2029.

Background

Xenotransplantation has faced cycles of hope and disappointment since the 1980s, with earlier attempts like the 2024 pig kidney transplant ending in patient death after 52 days. Recent advances in genetic engineering and immunology have improved organ compatibility. In 2026, a separate study highlighted the use of the cancer drug Teclistamab to reduce antibodies in highly sensitized patients, offering another potential solution to the organ shortage. The current case builds on these developments, demonstrating that pig organs can serve as a viable temporary bridge.

How outlets are covering it

The Guardian and New Scientist emphasize the individual success of Tim Andrews, highlighting the quality of life improvements and the record-breaking duration of the xenograft. The Financial Times broadens the scope, noting that five patients at Massachusetts General Hospital have undergone successful transplants since March 2024, with three lasting over eight months. STAT focuses on the critical question of whether pig kidneys produce antibodies that complicate future human transplants, confirming that they do not. While all sources agree on the milestone nature of the event, the Financial Times and New Scientist caution that high costs and the need for further research remain barriers to widespread adoption. The Guardian notes the single-patient limitation, while New Scientist mentions an MRSA infection that preceded the kidney's failure.

Why it matters

This case provides concrete evidence that pig kidneys can effectively bridge the gap for patients waiting for human donors, potentially saving lives and reducing the physical toll of dialysis. With approximately 600,000 people on dialysis in the US, the ability to use xenografts as a temporary solution could alleviate the strain on the organ donation system. The success of this trial supports the expansion of clinical trials and the eventual development of pig kidneys as a permanent destination therapy, addressing the critical organ shortage crisis.

What to watch

eGenesis plans to begin an expanded clinical trial with 33 patients in early 2027 across 10 US transplant centers, aiming for FDA marketing approval by the end of 2029. The company is also collaborating with PorMedTec to start kidney xenografts in Japan in 2028. Further case reports, including one where a patient has already surpassed the nine-month record, are expected to be published this year. Researchers will continue to monitor long-term safety and durability to determine if pig kidneys can eventually replace human transplants.